Showing 1201-1210 of 1325 results for "".
- EssilorLuxottica Chairman Leonardo Del Vecchio Passes Away at Age 87https://modernod.com/news/essilorluxottica-chairman-leonardo-del-vecchio-passes-away-at-age-87/2480931/Italian fashion icon Leonardo Del Vecchio, chairman of EssilorLuxottica, passed away at the age of 87, the company announced Monday. "The company expresses its deepest condolences to the family and to the global employee community for this enormous loss. The Board will m
- Alcon Announces Scientific Program at ASCRS 2022https://modernod.com/news/alcon-announces-scientific-program-at-ascrs-2022/2480782/Alcon will once again have a significant scientific presence at the American Society of Cataract and Refractive Surgery (ASCRS) 2022 annual meeting, taking place April 22-26 in Washington, DC. Approximately 150 abstracts feature Alcon’s leading ophthalmic products and equipment—with m
- Bausch Health Files for Solta IPOhttps://modernod.com/news/bausch-health-files-for-solta-ipo/2480629/Bausch Health Companies announced today that its wholly owned subsidiary, Solta Medical Corporation, has publicly filed for a proposed initial public offering (IPO). Solta, a provider of dermatology-focused lasers, has applied to list its common shares on the Nasdaq Global Select M
- Ocular Therapeutix Announces Topline Results for Phase 2 Clinical Trial of OTX-DED for the Short-Term Treatment of Dry Eye Diseasehttps://modernod.com/news/ocular-therapeutix-announces-topline-results-for-phase-2-clinical-trial-of-otx-ded-for-the-short-term-treatment-of-dry-eye-disease/2480496/Ocular Therapeutix announced positive topline results from its phase 2 clinical trial of OTX-DED (dexamethasone intracanalicular ophthalmic insert) for the short-term treatment of dry eye disease. The phase 2 clinical trial is a US-based, randomized, double-masked, vehicle-controlled, m
- Hoya Vision Care and Haag-Streit Partner to Combat Myopiahttps://modernod.com/news/hoya-vision-care-and-haag-streit-partner-to-combat-myopia/2480322/Hoya Vision Care announced a strategic partnership with Haag-Streit to help address the global rise of myopia in children. The global sales and marketing agreement creates a preferred partnership between Hoya Vision Care and Haag-Streit to provide eye care professionals (ECPs) with Lenstar M
- Azura Ophthalmics Appoints Steven Altschuler, MD, as Chair of the Boardhttps://modernod.com/news/azura-ophthalmics-appoints-steven-altschuler-md-as-chair-of-the-board/2479486/Azura Ophthalmics announced the appointment of Steven M. Altschuler, MD, as chair of its board of directors. Dr. Altschuler brings more than 20 years of experience building, scaling, and leading health care and biotechnology companies. He currently serves as managing director of Healthcare Ventur
- Iveric Bio to Present Zimura GATHER2 Enrollment and Retention Updates and New GATHER1 Post-Hoc Analyseshttps://modernod.com/news/iveric-bio-to-present-zimura-gather2-enrollment-and-retention-updates-and-new-gather1-post-hoc-analyses/2479306/Iveric bio announced that today at the company’s Virtual Symposium for Investors and Analysts, Arshad M. Khanani, MD, MA, of Sierra Eye Associates, and Chairman of the GATHER2 Steering Committee, will discuss an accelerated enrollment timeline and patient retention, including injection fidelity,
- Tarsus Pharmaceuticals and LianBio Announce Strategic Partnership to Develop and Commercialize TP-03 Drug Candidate in Greater Chinahttps://modernod.com/news/tarsus-pharmaceuticals-and-lianbio-announce-strategic-partnership-to-develop-and-commercialize-tp-03-drug-candidate-in-greater-china/2479026/Tarsus Pharmaceuticals and LianBio announced a strategic partnership to develop and commercialize TP-03 in Greater China (mainland China, Hong Kong, Taiwan, and Macau). TP-03 is a first-in-class investigational therapeutic in development for the treatment of Demodex blepharitis and M
- Clearside Biomedical Announces CLS-AX Presentation Delivered at Angiogenesis, Exudation, and Degeneration 2021 Programhttps://modernod.com/news/clearside-biomedical-announces-cls-ax-presentation-delivered-at-angiogenesis-exudation-and-degeneration-2021-program/2478874/Clearside Biomedical announced that David M. Brown, MD, delivered a presentation entitled, “Axitinib: A Novel TKI Delivered by Suprachoroidal Injection for AMD” at the virtual Angiogenesis, Exudation, and Degeneration 2021 program hosted by the University of Miami Health System Ba
- Samsara Vision Appoints Three New Members to the Board of Directorshttps://modernod.com/news/samsara-vision-appoints-three-new-members-to-the-board-of-directors/2478712/Samsara Vision, a developer of visual prosthetic devices for patients living with late-stage age-related macular degeneration (AMD), has announced the appointment of three new members to its Board of Directors: Jonathan H. Talamo, MD; Tracy M. Valorie; and David Schiff, joining Thierry Clidiere,